ATYR Company Profile and Key Details

NASDAQ : ATYR

aTyr Pharma

$0.85

-0.0034-0.40%

Open: 12:50 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

aTyr Pharma, Inc. (ATYR) stock declined over -0.40%, trading at $0.85 on NASDAQ, down from the previous close of $0.85. The stock opened at $0.86, fluctuating between $0.84 and $0.87 in the recent session.

Stock Snapshot

0.8534

Prev. Close

83.34M

Market Cap

0.8415

Day Low

-1.06

P/E Ratio

-0.8

EPS (TTM)

N/A

Cash Flow per Share

0.86

Open

98.05M

Number of Shares

0.8697

Day High

97.94%

Free Float in %

N/A

Book Value

426K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2026	0.85	0.87	0.83	0.85	697.36K
Apr 16, 2026	0.86	0.87	0.83	0.83	603.19K
Apr 14, 2026	0.82	0.88	0.82	0.84	653.53K
Apr 13, 2026	0.83	0.85	0.80	0.81	792.52K
Apr 10, 2026	0.77	0.85	0.75	0.83	973.91K
Apr 09, 2026	0.79	0.80	0.75	0.75	1.2M
Apr 08, 2026	0.83	0.84	0.79	0.80	682.69K
Apr 07, 2026	0.81	0.82	0.76	0.80	919.09K
Apr 06, 2026	0.84	0.87	0.82	0.82	728.43K
Apr 02, 2026	0.84	0.87	0.81	0.85	703.9K
Apr 01, 2026	0.80	0.86	0.79	0.85	1.8M
Mar 31, 2026	0.74	0.78	0.74	0.78	1.03M
Mar 30, 2026	0.75	0.76	0.72	0.73	1.47M
Mar 27, 2026	0.78	0.79	0.75	0.75	1.3M
Mar 25, 2026	0.80	0.84	0.77	0.80	1.47M
Mar 24, 2026	0.82	0.82	0.78	0.79	766.25K
Mar 23, 2026	0.83	0.85	0.80	0.83	892.9K
Mar 20, 2026	0.82	0.85	0.80	0.81	868.99K
Mar 19, 2026	0.82	0.84	0.79	0.83	1.05M
Mar 18, 2026	0.88	0.89	0.81	0.82	800.06K

Contact Details

San Diego, CA 92121

United States

https://www.atyrpharma.com 858 731 8389

About Company

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

The stock is currently mid-range between its 52-week high and low $0.64 and $7.29. With a market capitalization of about $83.34 million, aTyr Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.65). Key stats such as the average daily volume over the past year has been around 1.63 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, aTyr Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sanjay S. Shukla, the company employs approximately 56 people and listed since May 07, 2015. aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.

Technical Performance

ATYR has shown mixed momentum, gaining 3.44% over the past week and -30.74% over the past quarter, though year-to-date performance is down -9.78%. Short-term trend indicators are mixed aligned (SMA20 5.2%, SMA50 22.05%, SMA200 -62.64%). The stock’s 14-day RSI is 59.04 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -86.42% below its high and over 54.69% above its low. Average 10-day trading volume of 744.10 thousand shares is below the 3-month average of 1.65 million, indicating normal recent market interest.

Valuation Metrics

aTyr Pharma, Inc. trades at a P/E ratio of -1.13, slightly below the S&P 500 average, with a price-to-sales ratio of 440.4 and a price-to-book ratio of 1.24 suggesting the stock is closer to book value. The P/FCF stands at -1.35, also below market averages.

Dividend & Fair Value

aTyr Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

aTyr Pharma, Inc. generated EPS of -$0.83 over the past year. Five-year average earnings growth is 34.28%. Wall Street analysts project EPS growth of 16.68% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $1.00. The high target offers 2841.18% upside. The low target suggests 17.65% downside. The mean target is $9.10. This offers 970.59% upside. aTyr Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 30.0%. The prior quarter beat by 22.22%. Over the last six quarters, Apple has recorded several small beats. These include 4.55% in August 13, 2024.

Shareholding & Insider Activity

aTyr Pharma, Inc. has 98.05 million shares outstanding. The public float is 95.60 million shares, elevated short interest at 23.14% of float. This equals 18.97 million shares. The short ratio is 12.9 days. Institutional investors hold 64.35% of the float. Insiders own 1.43%. EcoR1 Capital Fund Qualified, L.P. holds 3.21 million shares, SCHIMMEL PAUL has 1.41 million shares and Shukla Sanjay has 153.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.42 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, aTyr Pharma has not generated any revenue.
On valuation metrics, aTyr Pharma trades at a P/E of -1.13, P/S of 440.40 and P/B of 1.24. The current ratio is 5.30 and quick ratio is 5.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 1614.03 days. Debt-to-equity is 0.18, supported by a cash flow-to-debt ratio of -5.15.

Price Forecast & Outlook

Our AI price prediction model suggests that aTyr Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.74%, with price expected at $0.83 by May 01, 2026, within a range of $0.79 to $0.87 3-Month Outlook: Projected fall of -14.46%, reaching $0.73 by July 16, 2026, with a range of $0.34 to $0.80. 1-Year Outlook: Projected gain of 1750.25%, with price at $15.79 by April 16, 2027, within a range of $8.81 to $24.45.

Key Takeaways

aTyr Pharma, Inc. (NASDAQ:ATYR) shares are flat -9.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows aTyr Pharma, Inc. trading at a premium to the broader market with a P/E of -1.13. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $20.73, suggesting 2329.11% upside. Our AI forecast model points to short-term weakness (-2.74% over two weeks), a medium-term fall (-14.46% over three months), and a longer-term gain (1750.25% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current aTyr Pharma, Inc. (ATYR) stock price?

aTyr Pharma, Inc. (NASDAQ: ATYR) stock price is $0.85 in the last trading session. During the trading session, ATYR stock reached the peak price of $0.87 while $0.84 was the lowest point it dropped to. The percentage change in ATYR stock occurred in the recent session was -0.4% while the dollar amount for the price change in ATYR stock was - $0.00.

ATYR's industry and sector of operation?

The NASDAQ listed ATYR is part of Biotechnology industry that operates in the broader Healthcare sector. aTyr Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ATYR?

No Data

How ATYR did perform over past 52-week?

ATYR's closing price is 33.34% higher than its 52-week low of $0.64 where as its distance from 52-week high of $7.29 is -88.29%.

How many employees does ATYR have?

Number of ATYR employees currently stands at 56.

Link for ATYR official website?

Official Website of ATYR is: https://www.atyrpharma.com

How do I contact ATYR?

ATYR could be contacted at phone 858 731 8389 and can also be accessed through its website. ATYR operates from 10240 Sorrento Valley Road, San Diego, CA 92121, United States.

How many shares of ATYR are traded daily?

ATYR stock volume for the day was 426K shares. The average number of ATYR shares traded daily for last 3 months was 1.63M.

What is the market cap of ATYR currently?

The market value of ATYR currently stands at $83.34M with its latest stock price at $0.85 and 98.05M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	56
Beta	0.65
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ATYR Company Profile and Key Details

aTyr Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics